Abide Therapeutics and SCYNEXIS Collaborate in Finding Novel Anti-Viral and Anti-Parasitic Agents
RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 03/28/12 -- SCYNEXIS, Inc. announced today that it has signed an agreement with Abide Therapeutics to collaborate in the search for novel anti-viral and anti-parasitic therapeutic compounds for human and animal health applications. Under the agreement, SCYNEXIS will screen, through its diverse biological screening platforms, Abide's proprietary serine hydrolase inhibitor library with the objective of identifying compounds for advancement to the preclinical stage.
"Abide Therapeutics has a unique technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. We are very excited to explore our discovery platform in the biological systems that SCYNEXIS brings to bear. Importantly, this collaboration has the potential to bring new therapies for a range of infectious diseases," said Alan Ezekowitz MBChB, D.Phil, president and chief executive officer of Abide Therapeutics.
"SCYNEXIS is gratified that Abide Therapeutics, with its innovative technology, is joining us in the search for innovative anti-parasitic technologies to address human and animal diseases," said Yves Ribeill, Ph.D., president and chief executive officer of SCYNEXIS. "We look forward to partnering our technologies in this exciting search."
About SCYNEXIS, Inc.
SCYNEXIS delivers integrated, efficient and innovative drug discovery and development solutions to our global health and pharmaceutical partners. Our record of success is exemplified by the eleven pre-clinical and clinical candidates delivered to our clients and partners in the last five years. SCYNEXIS' contract research and development services include Integrated Pharmaceutical Solutions, Discovery Research and Integrated Parasitology. Founded in 2000, SCYNEXIS is located in Research Triangle Park, North Carolina. For more information please visit www.scynexis.com
About Abide Therapeutics
Our mission is to develop innovative medicines for the benefit of human health that target serine hydrolases, one of the largest enzyme classes in nature with validated, but mostly untapped therapeutic potential.
For further information, please contact: SCYNEXIS, Inc. Terry Marquardt Executive Director, Market Development & Communications terry.marquardt@scynexis.com Tel: +1-919-544-8603 SCYNEXIS Media Contact: Rick Rountree Rick Rountree Communications, Inc. rick@rickrountree.com Tel. +1 919-878-1144 Abide Therapeutics Deborah Walker Administrator Debbie@abidetx.com Tel.+1- 760-315-6259
Source: SCYNEXIS, Inc.
Released March 28, 2012